| Thong Q. Le |
Thong Q. Le is a businessperson who founded Minimeals, Inc. and who has been the head of 14 different companies. Currently, he is President & Chief Executive Officer at Accelerator Services Corp, Chief Executive Officer & Director at ApoGen Biotechnologies, Inc., Chief Executive Officer & Director at Proniras Corp., Chief Executive Officer of Magnolia Neurosciences Corp., President, Chief Executive Officer & Director at ALSP Orchid Acquisition Corp. I, Chief Executive Officer & Director at Lydian Neurosciences Corp., Chief Executive Officer & Director at Automera Pte Ltd., CFO at Miro Tea and Director at Petra Pharma Corp. Thong Q. Le is also on the board of Acylin Therapeutics, Inc. (former Chief Executive Officer & Director), Briotech, Inc., Oerth Bio LLC and Ravenna Pharmaceuticals, Inc.
In the past he was Chief Executive Officer & Director at Oncofactor Corp., President & Chief Executive Officer of Minimeals, Inc., Director at AnswerDash, Inc., Principal at Capital Management Group, Inc., Chief Executive Officer & Director at Lodo Therapeutics Corp., President, Chief Executive Officer & Director at Rodeo Therapeutics Corp., Principal at Raymond James & Associates, Inc., Managing Director at WRF Capital and Chairman of Washington Biotechnology & Biomedical Association.
Mr. Le received an undergraduate degree from Harvard University. |
| Ian A. W. Howes |
Presently, Ian A. W. Howes is Chief Financial Officer & Managing Director at Accelerator Services Corp and Chief Financial Officer & Director at ALSP Orchid Acquisition Corp. I. Mr. Howes is also on the board of Alexandria Agtech and CFO at Cogenics Icoria, Inc. and CFO at Ensys, Inc.
In his past career Mr. Howes held the position of Chief Financial Officer & Vice President of Akebia Therapeutics, Inc., Chief Financial Officer & VP-Operations at Cogenics Icoria, Inc., CFO & Senior Vice President-Corporate Development at Serenex, Inc., Chief Financial Officer & Vice President of Aerpio Therapeutics, Inc., Chief Financial Officer for Scioderm, Inc., Chief Financial Officer for Heart Metabolics Ltd., CFO and SVP at Serenex, Inc., CFO at Jibu L3C and Consultant at Coopers & Lybrand (London).
He received an MBA from Kenan-Flagler Business School and an undergraduate degree from the University of Warwick. |
| Bruce Leonard Andrews Carter |
Bruce Leonard Andrews Carter is a businessperson who has been at the head of 8 different companies and currently holds the position of Non-Executive Chairman of Enanta Pharmaceuticals, Inc., Chairman at ALSP Orchid Acquisition Corp. I and Senior Advisor at Accelerator Services Corp. Dr. Carter is also on the board of Mirati Therapeutics, Inc., Dr. Reddy's Laboratories, Inc. and Aurigene Discovery Technologies Ltd. and Professor at the University of Washington.
He previously held the position of Chairman for Xencor, Inc., Chairman of Infectious Disease Research Institute, Executive Chairman for Infectious Disease Research Institute, Chief Scientific Officer & Executive VP at Novo Nordisk A, Chairman of ZymoGenetics, Inc., Executive Chairman of Immune Design Corp., Director at McAdams Wright Ragen, Inc., Head-Molecular Genetics at G.D. Searle & Co., Inc. and Executive Chairman for Global Alliance for TB Drug Development.
He received an undergraduate degree from The University of Nottingham and a doctorate from Queen Elizabeth College. |
| Kendall M. Mohler |
Kendall M. Mohler founded Emergent Product Development Seattle. Currently, he is CSO and SVP at Emergent Product Development Seattle. He is also on the board of Neuvogen, Inc. and Managing Director & Chief Development Officer at Accelerator Services Corp and Chief Development Officer for ALSP Orchid Acquisition Corp. I.
In the past he occupied the position of Chief Scientific Officer & Senior Vice President at Emergent Product Development Seattle, Chief Scientific Officer for ZetaRx Biosciences, Inc., Senior Vice President-Research at Juno Therapeutics, Inc. and Vice President-Biological Sciences at Immunex Corp.
He received an undergraduate degree from the University of Kansas and a doctorate from The University of Texas at Austin. |
| Andras Forgacs |
Andras Forgacs is an entrepreneur who founded The Resolution Project, Inc., Organovo, Inc., Modern Meadow, Inc. and Fork & Goode, Inc. Presently, Mr. Forgacs is Chairman of Fork & Goode, Inc., Chief Operating Officer at ALSP Orchid Acquisition Corp. I, Operating Partner at Accelerator Services Corp, Founding Pillar at Pillar Co Management LLC, Venture Partner at Starlight Ventures Management LLC and Advisor at EpiBone, Inc. He is also on the board of New Harvest, Inc. and Modern Meadow, Inc. (former Chief Executive Officer & Director) and Advisor at The Resolution Project, Inc.
In his past career he held the position of Principal at Citigroup, Inc., Consultant at McKinsey & Co., Inc., Managing Director at Richmond Global Ventures LLC and Director at Organovo, Inc.
Andras Forgacs received an MBA from the University of Pennsylvania and an undergraduate degree from Harvard University. |
| Kevin Chow |
Founder of Vitaeris, Inc., Kevin Chow currently is President for Incisive Genetics, Inc. and Operating Partner at Accelerator Services Corp. Dr. Chow is also Chief Business Officer at ALSP Orchid Acquisition Corp. I.
He previously was President, Chief Executive Officer & Director at Vitaeris, Inc., Director-Business Development at Corus Pharma, Inc. and Senior Director & Head-Business Development at Lundbeck Seattle BioPharmaceuticals, Inc.
He received an undergraduate degree, a graduate degree and a doctorate from the University of British Columbia. |
| Eugene W. Yeo |
Founder of 5 different companies, including: Locanabio, Inc., Proteona Pte Ltd. and Eclipse Bioinnovations, Inc. Eugene W. Yeo is an entrepreneur and currently holds the position of Senior Advisor at Accelerator Services Corp, Advisory Board at Allen Institute For Immunology, Advisory Board at Cell Applications, Inc. and Advisory Board at Sardona Therapeutics, Inc. and Co-Scientific Founder at Orbital Therapeutics, Inc. He is also Professor at the University of California San Diego and on the board of 5 other companies.
Eugene W. Yeo previously occupied the position of Advisory Board at Ribometrix, Inc.
Dr. Yeo received an undergraduate degree from the University of Illinois At Urbana–Champaign, a doctorate from Massachusetts Institute of Technology and an MBA from Rady School of Management at UC San Diego. |
| Mark W. Hahn |
Currently, Mark W. Hahn is Chief Financial Officer of Verona Pharma Plc. He is also on the board of ALSP Orchid Acquisition Corp. I.
In the past Mr. Hahn held the position of Chief Financial Officer at Charles & Colvard Ltd., Chief Financial Officer at Equitel, Inc., Chief Financial Officer & VP-Administration at Gigabeam Corp., Chief Financial Officer at BuildLinks, Inc., Chief Financial Officer for Athenix Corp., Chief Financial Officer & Executive Vice President at Cempra Pharmaceuticals, Inc., Chief Financial Officer & Executive Vice President at Cempra, Inc., Chief Financial Officer for Performaworks, Inc., Chief Financial Officer at Dova Pharmaceuticals, Inc. and Principal at Ernst & Young LLP.
Mr. Hahn received an undergraduate degree from the University of Wisconsin-Milwaukee. |
| Stephanie C. Read |
Currently, Stephanie C. Read occupies the position of President, Chief Executive Officer & Director at Ironshore Therapeutics, Inc. She is also on the board of ALSP Orchid Acquisition Corp. I and Vice President-Strategy & Development at CSL Ltd. (United States) and Member-Maryland Chapter at Project 1972, Inc.
Stephanie C. Read previously held the position of Executive Director-Corporate Strategy & Ventures at AstraZeneca PLC.
She received a graduate degree from The Johns Hopkins University and an undergraduate degree from Virginia Polytechnic Institute & State University. |
